Skip to main content

Mark Munger, PharmD, FCCP, FACC

Mark Munger, PharmD, FCCP, FACC, writes about medical matters of the heart and other internal organs.

Pharmacy Learning Network
Mark Munger, PharmD, explains why pharmacists need to be vigilant on medication administration records for all patients, and intervene when necessary to avoid unnecessary drug misadventuring—especially in heart failure.
Pharmacy Learning Network
Mark Munger, PharmD, explains why he believes it is important for pharmacists to stay current with new information about hypertension that will help them make rational decisions about identification, treatment, and referrals.
Pharmacy Learning Network
Mark Munger, PharmD, explains why community pharmacies provide a safety net for health care in rural counties.
Pharmacy Learning Network
Mark Munger, PharmD, discusses why the search for improving outcomes in HFrEF using newer anti-coagulants continues.
Pharmacy Learning Network
Mark Munger, PharmD, discusses recent study findings, which show that ranolazine increases the adverse effect profile of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, raising concern for patient safety.
Pharmacy Learning Network
In the final part of this series, Mark Munger, PharmD, provides potential solutions and insights into the future of community pharmacy in this era of pharmacy benefit managers.
Pharmacy Learning Network
In part 2 of this series, Mark Munger, PharmD, explains why the consequences of PBM practices on community pharmacy have wide implications to society, the profession, and the US health care system overall.
Pharmacy Learning Network
In this 3-part series, Mark Munger, PharmD, highlights the impact pharmacy benefit managers have on community pharmacies. In part 1, Dr Munger provides details on why he believes PBMs are directly or indirectly contributing to the closure of community pharmacies.
Pharmacy Learning Network
Mark Munger, PharmD, discusses the importance of sleep and highlights why poor sleep quality increases the risk of high blood pressure, cardiovascular disease, diabetes, and more.
Pharmacy Learning Network
Mark Munger, PharmD, explains why the phenotypic presentation of heart failure must be studied and highlights why he believes new therapeutic targets are needed based on the changing heart failure phenotype.
Back to Top